TABLE 2.
Important immune checkpoint inhibitors under clinical trial and on the market
| Target | Phase I | Phase II | Phase III | On the market |
|---|---|---|---|---|
| PD‐1 | CS1003 | MGA012 | Cemiplimab | Nivolumab |
| ZKAB001 | GLS‐010 | Camrelizumab | Pembrolizumab | |
| MK‐3475 | Balstilimab | HLX10 | Sintilimab | |
| PF‐06801591 | SG001 | Penpulimab | Tislelizumab | |
| AGEN1777 | BGB A317 | REGN2810 | Dostarlimab | |
| 609A | Retifanlimab | Spartalizumab | Toripalimab | |
| AMP‐224 | Zimberelimab | JS001 | ||
| PF‐06801591 | ||||
| INCMGA00012 | ||||
| BCD‐100 | ||||
| IBI308 | ||||
| JNJ‐63723283 | ||||
| PD‐L1 | LY3300054 | STI‐3031 | ZKAB001 | Atezolizumab |
| KN035 | CS1001 | SHR‐1316 | Avelumab | |
| BMS‐936559 | BGB‐A333 | Durvalumab | ||
| HLX20 | LP002 | Camrelizumab | ||
| MSB2311 | Bintrafusp alfa | |||
| BCD‐135 | ||||
| CTLA4 | CS1002 | Quavonlimab | Tremelimumab | Ipilimumab |
| BCD‐145 | AGEN1884 | MDX‐010 | ||
| ADU‐1604 | BCD‐217 | |||
| ONC‐392 | BMS‐986218 | |||
| ADG126 | CP 675,206 | |||
| ADG116 | IBI310 | |||
| TIGIT | JS006 | EOS‐448 | BGB‐A1217 | |
| ASP8374 | Ociperlimab | Tiragolumab | ||
| COM902 | BMS‐986207 | |||
| AZD2936 | Etigilimab | |||
| EOS‐448 | ||||
| IBI939 | ||||
| LAG‐3 | REGN3767 | IMP321 | ||
| TSR‐033 | Relatlimab | |||
| Sym022 | LAG525 | |||
| INCAGN02385 | ||||
| TIM‐3 | Sym023 | TSR‐022 | ||
| INCAGN2390 | MBG453 | |||
| LY3321367 | BMS‐986258 | |||
| SHR‐1702 | INCAGN02390 | |||
| Cobolimab | ||||
| VISTA | JNJ‐61610588 | |||
| B7‐H3 | MGD009 | Enoblituzumab | ||
| Dual PD‐1/PD‐L1 | IBI318 | |||
| Dual PD‐1/TIGIT | AZD2936 | |||
| Dual PD‐1/TIM‐3 | RO7121661 | AZD7789 | ||
| Dual PD‐1/LAG‐3 | RO7247669 | MGD013 | ||
| MGD013 | ||||
| Dual PD‐1/VEGF | AK112 | |||
| Dual PD‐1/CTLA4 | AK104 | |||
| BCD‐217 | ||||
| Dual PD‐L1/LAG‐3 | FS118 | RO7247669 | ||
| IBI323 | ||||
| Dual PD‐L1/TIM‐3 | LY3415244 | RO7121661 | ||
| Dual PD‐L1/4‐1BB | ABL503 | |||
| Dual PD‐L1/VISTA | CA‐170 | |||
| Dual PD‐L1/TGF‐β | Y101D | SHR1701 | M7824 |
Note: All the data source information is from ClinicalTrials.gov.
Abbreviations: CTLA4, cytotoxic lymphocyte‐associated protein 4; LAG‐3, lymphocyte activation gene 3; PD‐1, programmed cell death 1; PD‐L1, programmed death ligand‐1; TIGIT, T cell immunoglobulin and ITIM domain; TIM‐3, T‐cell immunoglobulin‐3.